0.22%
-0.92%
-16.56%
-21.45%
16.77%
69.29%
154.82%
AI Spotlight on MRUS
Company Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands.Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.
In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145.The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Market Data
| Last Price | 41.66 |
| Change Percentage | 0.22% |
| Open | 41.82 |
| Previous Close | 41.57 |
| Market Cap ( Millions) | 2852 |
| Volume | 71384 |
| Year High | 61.61 |
| Year Low | 35.06 |
| M A 50 | 42.99 |
| M A 200 | 49.05 |
Financial Ratios
| FCF Yield | -5.46% |
| Dividend Yield | 0.00% |
| ROE | -45.38% |
| Debt / Equity | 0.25% |
| Net Debt / EBIDTA | 173.25% |
| Price To Book | 4.04 |
| Price Earnings Ratio | -11.63 |
| Price To FCF | -18.33 |
| Price To sales | 79.38 |
| EV / EBITDA | -9.73 |
News
- Jan -20 - Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff
- Jan -13 - Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
- Dec -16 - Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
- Dec -07 - Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
- Dec -05 - Merus Scores Its First FDA Approval For Lung Cancer Drug
- Dec -04 - Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
- Dec -02 - Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
- Dec -01 - Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
- Nov -21 - Biotech Stock Boosted on Brand-New 'Buy' Rating
- Nov -06 - Merus to Present at Upcoming Investor Conferences
- Nov -05 - Merus: Petosemtamab Set Up For December 2024 Data Presentation
- Nov -05 - Merus Receives FDA extension of PDUFA for zenocutuzumab
- Oct -31 - Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates
- Oct -31 - Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
- Aug -14 - Merus: Great European Oncology Developer, But Properly Valued
- Aug -01 - Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates
- Aug -01 - Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
- Jul -29 - Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Jul -24 - Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
- Jun -03 - Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Innovative Therapeutics
Expected Growth : 11.3 %
What the company do ?
Innovative Therapeutics from Merus N.V. develops bispecific antibodies to treat various cancers, leveraging its proprietary Biclonics technology to enhance efficacy and safety.
Why we expect these perspectives ?
Merus N.V.'s Innovative Therapeutics segment growth of 11.3% is driven by increasing adoption of bispecific antibodies, strong pipeline of novel oncology candidates, and strategic partnerships. Additionally, growing demand for targeted therapies, expansion into new markets, and investments in research and development are contributing to the segment's rapid growth.
Merus N.V. Products
| Product Range | What is it ? |
|---|---|
| MCLA-117 | A bispecific antibody targeting Lgr5 and EGFR, for the treatment of solid tumors |
| MCLA-128 | A bispecific antibody targeting HER2 and HER3, for the treatment of breast cancer and gastric cancer |
| MCLA-158 | A bispecific antibody targeting Lgr5 and EGFR, for the treatment of solid tumors |
| Zenocutuzumab (MCLA-128) | A bispecific antibody targeting HER2 and HER3, for the treatment of breast cancer and gastric cancer |
| Petosemtiv (MCLA-129) | A bispecific antibody targeting EGFR and c-MET, for the treatment of non-small cell lung cancer |
Merus N.V.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Merus N.V. is moderate due to the presence of alternative products in the market.
Bargaining Power Of Customers
The bargaining power of customers is low for Merus N.V. due to the company's strong brand reputation and customer loyalty.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate for Merus N.V. due to the presence of multiple suppliers in the market.
Threat Of New Entrants
The threat of new entrants is high for Merus N.V. due to the low barriers to entry in the market.
Intensity Of Rivalry
The intensity of rivalry is high for Merus N.V. due to the presence of several competitors in the market.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 3.30% |
| Debt Cost | 9.42% |
| Equity Weight | 96.70% |
| Equity Cost | 9.42% |
| WACC | 9.42% |
| Leverage | 3.41% |
Merus N.V. : Quality Control
Merus N.V. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| JAZZ | Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of … |
| CRSP | CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its … |
| ZEAL.CO | Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, … |
| ALKS | Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its … |
| GMAB.CO | Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Genmab
A-Score
1-Year Total Return ->
🥈
Jazz Pharmaceuticals
A-Score
1-Year Total Return ->
🥉
Alkermes
A-Score
1-Year Total Return ->
4
Zealand Pharma
A-Score
1-Year Total Return ->
5
Merus
A-Score
1-Year Total Return ->
6
